The randomized controlled trial, known as ROADS, was co-led by Jeffrey Weinberg, M.D., professor of Neurosurgery, and Thomas Beckham, M.D., Ph.D., assistant professor of CNS Radiation Oncology, both of MD Anderson. It is the first Phase 3 study to directly compare GammaTile cesium-131 collagen tile-based radiation therapy, abbreviated TBRT, against postoperative stereotactic radiation therapy, or SRT, which has long been the accepted standard following brain metastasis surgery. The trial was sponsored by GT Medical Technologies, Inc., the developer of the GammaTile device, which is cleared by the U.S. Food and Drug Administration.

The technology behind TBRT is elegantly simple in concept yet sophisticated in its radiobiology. GammaTile consists of small collagen tiles, each roughly the size of a postage stamp, embedded with evenly spaced seeds containing cesium-131, a radioactive isotope. After a neurosurgeon removes a brain metastasis, the tiles are essentially wallpapered onto the walls of the resulting surgical cavity. From that position, the seeds deliver a continuous, low-dose stream of therapeutic radiation over the course of several weeks, precisely targeting the cavity surface where residual microscopic tumor cells are most likely to linger after resection.

A critical advantage of this brachytherapy approach lies in its dose distribution. The radiation emitted by cesium-131 falls off very rapidly with distance, a property known as steep dose fall-off. This means that while the cavity lining receives an intensified, escalated dose capable of destroying microscopic disease, the surrounding healthy brain tissue is exposed to very little radiation. The collagen matrix itself is biocompatible and gradually breaks down in the body, allowing the treatment to be completed without any need for the patient to return for repeated radiation sessions.

The clinical results reported in the ROADS trial are striking by any measure. At the one-year mark, only 1.3 percent of patients treated with tile-based radiation therapy experienced a recurrence of their tumor at the surgical site, compared with 15.4 percent of patients who received standard postoperative stereotactic radiation. Weinberg emphasized the magnitude of this difference, noting that implanting the radioactive tiles at the time of surgery guarantees that patients receive their treatment immediately, along with focal dose escalation, thereby having a meaningful impact on local tumor control. From a patient standpoint, he explained, the trial shows nearly four times the length of local control and an increase in overall survival, a difference he described as massive rather than marginal.

Survival outcomes were equally compelling. Median overall survival, a key secondary endpoint of the trial, reached 42.5 months in the TBRT arm, more than double the 17.6 months observed in patients treated with standard stereotactic radiation. For a patient population in which every additional month of quality survival matters enormously, a gain of nearly two years represents a transformative shift in prognosis. Equally important, the improved outcomes did not come at the cost of increased toxicity. The trial found no differences in serious treatment-related side effects between the two groups, and the rate of radiation necrosis, a feared late complication of radiation therapy for brain metastases, was nearly identical between the TBRT and SRT arms, underscoring the safety profile of the implanted tiles.

Beyond efficacy and safety, TBRT offers a significant logistical advantage that may partly explain its survival benefit. Postoperative stereotactic radiation is typically scheduled weeks after surgery, and guidelines suggest it should occur within four weeks of resection to maximize effectiveness. Yet in real-world practice, patients often face postoperative complications, scheduling delays, and interruptions to systemic cancer therapies, and approximately 20 percent of patients ultimately fail to receive their planned postoperative SRT, with measurable compromise in their outcomes. With TBRT, the radiation is delivered in a single step during the operation itself, with most patients completing their cranial radiation in just one day, compared with a median of 32 days for those needing to arrange postoperative SRT. This rapid completion potentially allows patients to return to systemic treatments that control their broader disease much sooner.

Beckham highlighted this convenience factor as a surprising and welcome finding, noting that the results are dramatically better than current alternatives and provide improved patient convenience by helping patients move past the roadblock of a brain metastasis diagnosis more quickly. Being able to get patients over that roadblock and back to managing their overall cancer, he observed, appears to positively impact more than just the surgical outcome, something the research team had not anticipated to such a magnitude. The observation suggests that the benefits of immediate, embedded radiation extend beyond pure tumor biology into the practical realities of cancer care coordination.

The clinical context makes these findings especially significant. Brain metastases are a common and devastating complication of advanced solid tumors, arising in many patients with cancers such as lung cancer, breast cancer, and melanoma, and they can profoundly affect both treatment planning and prognosis. Surgery is typically reserved for larger or symptomatic metastases that cause pressure on the brain or neurological deficits. However, even with meticulous resection, microscopic tumor cells remain in the cavity wall, and without any adjuvant radiation, recurrence at the surgical site occurs 50 to 60 percent of the time. Stereotactic radiation therapy was developed precisely to address this risk, delivering highly focused, dose-escalated beams to destroy residual cells while sparing healthy tissue, but its dependence on postoperative scheduling has left a persistent gap in care.

The ROADS investigators hope their results will accelerate guideline adoption and broader clinical rollout of tile-based radiation therapy, potentially reshaping the management of brain metastases worldwide. Future research will explore how widely TBRT can be integrated into metastasis care and whether the technique holds promise for other tumor types beyond brain metastases. If the trial’s remarkable combination of superior tumor control, doubled survival, equivalent safety, and streamlined treatment logistics is confirmed in practice, the postage-stamp-sized tiles wallpapered into surgical cavities may well become a defining advance in neuro-oncology, offering patients with brain metastases not only more time but a faster, simpler path back to treating their cancer as a whole.

Subject of Research: Tile-based brachytherapy with cesium-131 for preventing recurrence of surgically resected brain metastases

Article Title: Researchers suggest tile-based radiation therapy as standard of care to lower risk of recurrence in brain metastases

Article References: Researchers suggest tile-based radiation therapy as standard of care to lower risk of recurrence in brain metastases. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: brain metastases, tile-based radiation therapy, GammaTile, brachytherapy, cesium-131, stereotactic radiation therapy, surgical resection, Phase 3 trial, MD Anderson Cancer Center, radiation necrosis, tumor recurrence, neuro-oncology